By Counterforce Health Team in Synagis (palivizumab) —

How to Get Synagis (Palivizumab) Covered by Humana in Michigan: Complete Authorization Guide

Answer Box: Getting Synagis Covered by Humana in Michigan

Synagis (palivizumab) requires prior authorization from Humana for high-risk infants. The fastest path to approval: 1) Confirm your child meets high-risk criteria (premature birth ≤35 weeks, chronic lung disease, or significant heart conditions), 2) Have your pediatrician submit the prior authorization through CenterWell Specialty Pharmacy at 855-264-0104, and 3) Include complete clinical documentation showing RSV risk factors. If denied, Michigan law gives you 127 days to file an external review with guaranteed 72-hour expedited decisions for urgent cases.

Table of Contents

Who Should Use This Guide

This guide helps families and healthcare providers get Synagis (palivizumab) covered by Humana plans in Michigan. You'll need this if your high-risk infant requires RSV prevention but faces coverage barriers.

Expected outcome: With proper documentation and submission, most eligible infants get approved within 30 days. Michigan's strong consumer protection laws ensure fair appeals when denials occur.

Key scenarios:

  • Premature infants under 6 months during RSV season
  • Children with chronic lung disease or significant heart conditions
  • Previous Humana denials requiring appeals
  • Switching from other RSV preventive treatments

Member & Plan Basics

Coverage Requirements

Active Humana Coverage: Verify your child is enrolled and coverage is active through the Humana member portal or by calling the member services number on your insurance card.

Plan Types: Synagis coverage applies to:

  • Humana Medicare Advantage (for eligible pediatric beneficiaries)
  • Humana Medicaid plans in Michigan
  • Commercial Humana plans with pediatric coverage
Note: All Humana plans require prior authorization for Synagis, regardless of plan type.

Authorization Timeline

Plan Type Standard Decision Expedited Decision
Medicare Advantage 30 days 72 hours
Medicaid 15 days 72 hours
Commercial 15 days 72 hours

Source: Michigan Department of Insurance and Financial Services

Clinical Criteria for Synagis

High-Risk Eligibility

Synagis is approved for infants and children meeting specific high-risk criteria aligned with American Academy of Pediatrics guidelines:

Premature Infants:

  • Born at ≤35 weeks gestational age
  • Under 6 months old at RSV season start
  • No other major risk factors required

Chronic Lung Disease:

  • Born before 32 weeks gestation
  • Required oxygen >21% for ≥28 days after birth
  • Under 24 months old with ongoing medical management

Congenital Heart Disease:

  • Hemodynamically significant conditions
  • Requires ongoing cardiac medications or monitoring
  • Documented by pediatric cardiology
Important: Nirsevimab (Beyfortus) is now preferred for broader infant populations. Synagis is reserved for specific high-risk groups when Beyfortus isn't suitable.

Seasonal Limitations

  • Maximum 5 monthly doses per RSV season
  • Typically November through March in Michigan
  • Must discontinue after any RSV hospitalization

Coding & Billing Requirements

Essential Codes

HCPCS Code: J90378 (Injection, palivizumab, 50 mg)

Key ICD-10 Diagnosis Codes:

  • P07.20-P07.26: Extreme immaturity/low birth weight
  • P27.1: Bronchopulmonary dysplasia
  • Q20-Q28: Congenital heart malformations
  • Z87.891: Personal history of nicotine dependence (maternal smoking history)

Dosing: 15 mg/kg intramuscularly every 28-30 days

Billing Tip: Match ICD-10 codes precisely to your child's documented risk factors. Vague or incorrect coding is a common denial reason.

Documentation Packet

Medical Necessity Letter Components

Your pediatrician's letter must include:

  1. Patient demographics: Full name, DOB, gestational age at birth, current weight
  2. Risk factor documentation: Specific conditions qualifying for Synagis
  3. Clinical justification: Why Synagis is medically necessary over alternatives
  4. Treatment plan: Dosing schedule, administration site, monitoring plan
  5. Prior therapy: Documentation of why Beyfortus isn't appropriate (if applicable)

Required Attachments

  • Recent pediatric visit notes (within 30 days)
  • Specialist consultations (cardiology/pulmonology if applicable)
  • Hospital discharge summaries showing risk factors
  • Growth charts and current vital signs
  • Laboratory results supporting diagnosis

From Our Advocates: "The most successful Synagis approvals include a one-page summary from the pediatrician highlighting the three strongest risk factors, with specific dates and measurements. This helps reviewers quickly identify eligibility without digging through lengthy medical records."

Submission Process

CenterWell Specialty Pharmacy (Preferred)

Humana directs Synagis prescriptions through CenterWell Specialty Pharmacy:

Contact Information:

  • Phone: 855-264-0104
  • Fax: 800-345-8534
  • Electronic prescribing: Select "CenterWell Specialty Pharmacy" in your e-prescribing system

Prior Authorization Forms

Use Humana's official Synagis order form (verify current version). Key sections that commonly cause rejections:

  • Patient weight: Must be current (within 2 weeks)
  • Gestational age: Exact weeks and days, not rounded
  • Risk factor checkboxes: Complete all applicable sections
  • Prescriber signature: Must be original, not stamped

Submission Methods

  1. Electronic: Through Humana provider portal (fastest)
  2. Fax: 877-486-2621 for medication prior authorizations
  3. Phone: 855-264-0104 for CenterWell submissions
Tip: Always request a confirmation number and save submission receipts.

Specialty Pharmacy Routing

CenterWell Services

Once approved, CenterWell Specialty Pharmacy coordinates:

  • Medication delivery: Home or physician office
  • Administration support: Home health nursing if prescribed
  • Financial assistance: Patient assistance program coordination
  • Clinical monitoring: Side effect management and adherence support

Alternative Distributors

If CenterWell cannot fulfill your prescription, other authorized Synagis distributors include:

  • Accredo Specialty Pharmacy
  • AllianceRx Walgreens Pharmacy
  • Advanced Pharmacy Solutions
Note: Always verify with Humana before using alternative distributors to ensure coverage.

After Submission

Tracking Your Request

Confirmation steps:

  1. Record submission date and confirmation number
  2. Set calendar reminder for decision deadline
  3. Check status weekly through provider portal or member services

Expected timelines:

  • Standard requests: 15-30 days depending on plan type
  • Expedited requests: 72 hours with physician attestation of urgency

What to Document

Keep detailed records including:

  • All submission confirmations
  • Phone call logs with dates and representative names
  • Any additional information requests
  • Decision letters (approval or denial)

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
"Not high-risk enough" Submit specialist consultation Cardiology or pulmonology notes
"Beyfortus preferred" Document contraindication/unavailability Prescriber attestation letter
"Outside RSV season" Provide local virology data Lab reports showing >10% RSV positivity
"Incomplete documentation" Resubmit with all attachments Complete medical records checklist
"Exceeds quantity limits" Justify extended treatment Clinical notes supporting need

Prevention Tips

  1. Double-check eligibility against current AAP guidelines before submitting
  2. Use exact gestational age (weeks and days, not approximations)
  3. Include specialist notes for cardiac or pulmonary conditions
  4. Submit during RSV season (typically October-April in Michigan)
  5. Verify current forms - Humana updates prior authorization forms regularly

Appeals Process in Michigan

Internal Appeals (First Step)

If Humana denies coverage:

  1. File within 60 days of denial notice
  2. Submit through: Member portal, phone (member services number on card), or mail
  3. Include: Original denial letter, new clinical information, prescriber support letter
  4. Timeline: 30 days for standard, 72 hours for expedited

External Review (Michigan DIFS)

Michigan's Department of Insurance and Financial Services offers independent review:

Eligibility: After completing Humana's internal appeal process Timeline to file: 127 days from final internal denial Decision timeframe: 60 days standard, 72 hours expedited Cost: Free to consumers

How to file:

Expedited Appeals

For urgent Synagis needs during RSV season:

  • Physician letter required stating delay would harm patient
  • 72-hour decision guaranteed by Michigan law
  • Binding decision - if approved, Humana must comply immediately

Quick Reference Checklist

Before You Start

  • Verify active Humana coverage
  • Confirm child meets high-risk criteria
  • Gather complete medical records
  • Identify current RSV season dates

Documentation Checklist

  • Medical necessity letter from pediatrician
  • Recent visit notes (within 30 days)
  • Specialist consultations if applicable
  • Hospital discharge summaries
  • Current weight and vital signs
  • Complete Humana Synagis order form

Submission Checklist

  • Contact CenterWell Specialty Pharmacy (855-264-0104)
  • Submit via preferred method (electronic, fax, phone)
  • Request confirmation number
  • Set calendar reminder for decision deadline
  • Prepare appeal documents in case of denial

Getting help with complex insurance coverage decisions? Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, identifying coverage gaps, and drafting evidence-backed rebuttals aligned to each plan's specific requirements. Their platform helps patients, clinicians, and specialty pharmacies navigate prior authorization processes more effectively, reducing delays in accessing critical medications like Synagis.

For additional support with your Synagis coverage journey, Counterforce Health can help analyze your specific situation and develop a targeted strategy for approval or appeal.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage processes and should not be considered medical or legal advice. Coverage decisions depend on individual circumstances, plan benefits, and clinical factors. Always consult with your healthcare provider about treatment decisions and contact your insurance plan directly for coverage questions. Michigan insurance regulations and Humana policies may change; verify current requirements through official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.